Specification Sheet
| Pos |
No. |
Sex |
Age |
Organ |
Pathology diagnosis |
Grade |
Gleason Grade |
Gleason Score |
TNM |
Type † |
|
A1 |
1 |
M |
69 |
Prostate |
Adenocarcinoma |
3 |
4 |
3+4 |
T2NxM0 |
Malignant |
|
A2 |
2 |
M |
69 |
Prostate |
Adenocarcinoma |
3 |
4 |
3+5 |
T2NxM0 |
Malignant |
|
A3 |
3 |
M |
73 |
Prostate |
Cancer adjacent normal prostatic tissue (hyperplasia) |
– |
– |
– |
– |
NAT |
|
A4 |
4 |
M |
73 |
Prostate |
Cancer adjacent normal prostatic tissue (hyperplasia) |
– |
– |
– |
– |
NAT |
|
A5 |
5 |
M |
60 |
Prostate |
Adenocarcinoma |
1 |
2 |
2+1 |
T4N1M1c |
Malignant |
|
A6 |
6 |
M |
60 |
Prostate |
Adenocarcinoma |
1 |
2 |
2+1 |
T4N1M1c |
Malignant |
|
A7 |
7 |
M |
77 |
Prostate |
Cancer adjacent normal prostatic tissue (sparse) |
– |
– |
– |
– |
NAT |
|
A8 |
8 |
M |
77 |
Prostate |
Cancer adjacent normal prostatic tissue |
– |
– |
– |
– |
NAT |
|
B1 |
9 |
M |
64 |
Prostate |
Adenocarcinoma (prostatic tissue) |
– |
– |
– |
T2NxM0 |
Malignant |
|
B2 |
10 |
M |
64 |
Prostate |
Adenocarcinoma |
2 |
2 |
2+3 |
T2NxM0 |
Malignant |
|
B3 |
11 |
M |
27 |
Prostate |
Cancer adjacent normal prostatic tissue |
– |
– |
– |
– |
NAT |
|
B4 |
12 |
M |
27 |
Prostate |
Cancer adjacent normal prostatic tissue |
– |
– |
– |
– |
NAT |
|
B5 |
13 |
M |
64 |
Prostate |
Adenocarcinoma |
2–3 |
3 |
3+4 |
T3NxM1b |
Malignant |
|
B6 |
14 |
M |
64 |
Prostate |
Adenocarcinoma |
2–3 |
3 |
3+4 |
T3NxM1b |
Malignant |
|
B7 |
15 |
M |
84 |
Prostate |
Cancer adjacent normal prostatic tissue (hyperplasia) |
– |
– |
– |
– |
NAT |
|
B8 |
16 |
M |
84 |
Prostate |
Cancer adjacent normal prostatic tissue (hyperplasia) |
– |
– |
– |
– |
NAT |
|
C1 |
17 |
M |
75 |
Prostate |
Adenocarcinoma |
1 |
1 |
1+2 |
T2N1M1c |
Malignant |
|
C2 |
18 |
M |
75 |
Prostate |
Adenocarcinoma |
1 |
1 |
1+3 |
T2N1M1c |
Malignant |
|
C3 |
19 |
M |
80 |
Prostate |
Cancer adjacent normal prostatic tissue |
– |
– |
– |
– |
NAT |
|
C4 |
20 |
M |
80 |
Prostate |
Cancer adjacent normal prostatic tissue |
– |
– |
– |
– |
NAT |
|
C5 |
21 |
M |
75 |
Prostate |
Adenocarcinoma |
2 |
3 |
3+3 |
T4N1M1b |
Malignant |
|
C6 |
22 |
M |
75 |
Prostate |
Adenocarcinoma |
2 |
3 |
3+4 |
T4N1M1b |
Malignant |
|
C7 |
23 |
M |
21 |
Prostate |
Cancer adjacent normal prostatic tissue |
– |
– |
– |
– |
NAT |
|
C8 |
24 |
M |
21 |
Prostate |
Cancer adjacent normal prostatic tissue |
– |
– |
– |
– |
NAT |
|
–
|
– |
M |
58 |
Skin |
Malignant melanoma (tissue marker) |
– |
|
|
|
Malignant |
† For precise diagnosis, refer to pathology description.
**The grade 1-3 (or I-III) in Pathology Diagnosis is equivalent to well-differentiated, moderately-differentiated or poorly differentiated, respectively, under microscope.
Grade 1 or well-differentiated: Cells appear normal and are not growing rapidly.
Grade 2 or moderately-differentiated: Cells appear slightly different than normal.
Grade 3 or poorly differentiated: Cells appear abnormal and tend to grow and spread more aggressively.
Grade 4 or undifferentiated: *(for certain tumors), features are not significantly distinguishing to make it look any different from undifferentiated cancers which occur in other organs.
TNM grading:
T - Primary tumor
Tx - Primary tumor cannot be assessed
T0 - No evidence of primary tumor
Tis - Carcinoma in situ; intraepithelial or invasion of lamina propria
T1 - Tumor invades submucosa
T2 - Tumor invades muscularis propria
T3 - Tumor invades through muscularis propria into subserosa or into non-peritonealized pericolic or perirectal tissues.
T4 - Tumor directly invades other organs or structures and/or perforate visceral peritoneum
N - Regional lymph nodes
Nx - Regional lymph nodes cannot be assessed
N0 - No regional lymph node metastasis
N1 - Metastasis in 1 to 3 regional lymph nodes
N2 - Metastasis in 4 or more regional lymph nodes
M - Distant metastasis
Mx - Distant metastasis cannot be assessed
M0 - No distant metastasis
M1 - Distant metastasis
